Disease · MONDO_0001014

chronic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic leukemia. Diseases, record MONDO_0001014. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001014

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic leukemia; Open Targets
Open Targets ID: MONDO_0001014; Open Targets
Other names: chronic leukaemia (disease), chronic leukemia (disease), leukaemia (disease), chronic, leukemia (disease), chronic; Open Targets
Disease Ontology: DOID:1036; Disease Ontology
NCI Thesaurus: C3483; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 15 drugs, from PMDA; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CRISANTASPASE	CHEMBL2108931	Enzyme	Approval	PMDA	1	0	0	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
LENOGRASTIM	CHEMBL2109128	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEGFILGRASTIM	CHEMBL1201568	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 1	https://conductscience.org/library/genes/3570	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 1	https://conductscience.org/library/genes/5133	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00074490	Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers	Phase 2	442	2018-12-31	Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00003838	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow	Phase 2	202	2022-10-07	Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	CYCLOSPORINE, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT00587054	Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders	Phase 2	129	2017-03-10	Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)	FLUDARABINE, THIOTEPA	Its record names the disease	ClinicalTrials.gov
NCT00378534	Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants	Phase 2	116	2015-01-06	Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00467961	Stem Cell Transplantation for Patients With Cancers of the Blood	Phase 2	61	2015-01-06	CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia, MDS (Myelodysplastic Syndrome)	CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00005785	Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer	Phase 1	30		Hematologic Neoplasm, HIV Infection	CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT03588936	Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant	Phase 1	2		Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes	NIVOLUMAB, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00002502	Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	Phase 2			Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes	BUSULFAN, CYCLOPHOSPHAMIDE, CYTARABINE	Its record names the disease	ClinicalTrials.gov
NCT00077558	3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome	Phase 1			Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases	FLUDARABINE, TRIAPINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
T Cell Depletion Transplant Participants vs Stem Cell Donors: deaths from any cause	14 of 58	0 of 58	116	NCT00378534	Trial comparisons
T Cell Depletion Transplant Participants vs Stem Cell Donors: serious adverse events	14 of 58	0 of 58	116	NCT00378534	Trial comparisons
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants That Remained Disease-free Survival	26 of 43	56 of 57	100	NCT00003838	Trial comparisons
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Who Experienced Transplant Related Mortality	5 of 43	4 of 57	100	NCT00003838	Trial comparisons
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Overall Survival	17 of 43	48 of 57	100	NCT00003838	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23426943	RESULT	1	PubMed
21684344	RESULT	1	PubMed
17640728	RESULT	1	PubMed
29705733	DERIVED	1	PubMed
29674506	DERIVED	1	PubMed
23813900	DERIVED	1	PubMed
23710698	DERIVED	1	PubMed
23524640	DERIVED	2	PubMed
23065508	DERIVED	1	PubMed
22133778	DERIVED	2	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001014

GET https://conductscience.org/api/diseases/v1/MONDO_0001014/drugs

API reference For AI assistants